KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by Brokerages

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) has been assigned a consensus rating of "Buy" from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $24.83.

A number of research firms have recently weighed in on KALV. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an "outperform" rating and a $19.00 price target on the stock. Jones Trading reissued a "buy" rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Finally, TD Cowen started coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $30.00 target price for the company.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock traded up $0.79 during midday trading on Wednesday, reaching $12.79. The stock had a trading volume of 128,620 shares, compared to its average volume of 402,414. KalVista Pharmaceuticals has a twelve month low of $7.30 and a twelve month high of $15.50. The firm has a market cap of $635.62 million, a price-to-earnings ratio of -3.49 and a beta of 0.39. The firm's fifty day simple moving average is $11.32 and its two-hundred day simple moving average is $10.31.

Insider Buying and Selling

In other news, CEO Benjamin L. Palleiko sold 5,104 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the transaction, the chief executive officer now owns 278,855 shares in the company, valued at approximately $2,738,356.10. This represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the stock in a transaction dated Wednesday, April 9th. The stock was bought at an average cost of $9.42 per share, with a total value of $235,500.00. Following the completion of the purchase, the insider now owns 5,303,985 shares of the company's stock, valued at approximately $49,963,538.70. The trade was a 0.47 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 261,055 shares of company stock valued at $2,397,646 and have sold 17,292 shares valued at $184,625. 10.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. FMR LLC raised its position in KalVista Pharmaceuticals by 22.9% in the 3rd quarter. FMR LLC now owns 66,423 shares of the specialty pharmaceutical company's stock worth $769,000 after buying an additional 12,397 shares during the last quarter. State Street Corp raised its stake in KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company's stock worth $14,725,000 after buying an additional 515,179 shares in the last quarter. Wellington Management Group LLP raised its position in shares of KalVista Pharmaceuticals by 40.3% in the 3rd quarter. Wellington Management Group LLP now owns 117,923 shares of the specialty pharmaceutical company's stock valued at $1,366,000 after purchasing an additional 33,900 shares during the last quarter. Barclays PLC lifted its holdings in KalVista Pharmaceuticals by 418.5% in the third quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company's stock valued at $778,000 after acquiring an additional 54,257 shares during the period. Finally, Geode Capital Management LLC increased its stake in KalVista Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 830,984 shares of the specialty pharmaceutical company's stock worth $9,624,000 after buying an additional 24,713 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).